Dupilumab
Dupilumab is a monoclonal antibody used to treat moderate-to-severe atopic dermatitis, asthma with specific inflammatory features, chronic rhinosinusitis with nasal polyps, and other approved type 2 inflammatory conditions, depending on the patient’s age and local regulatory approvals. It works by blocking interleukin-4 receptor alpha (IL-4Rα), inhibiting IL-4 and IL-13 signalling involved in allergic and inflammatory responses. Dupilumab is administered by subcutaneous injection, commonly using a prefilled syringe or injection pen. Common side effects include injection-site reactions, conjunctivitis, eyelid inflammation, and cold-sore infections. Patients should be monitored for significant eye symptoms and hypersensitivity reactions, and existing asthma treatment should not be discontinued without medical advice. Treatment requires appropriate clinical assessment and supervision by a qualified healthcare professional.
Dupilumab was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:
is okay
The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.
Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Dupilumab, subject to confirmation of its current regulatory status and eligibility for import into India.
The export of Dupilumab from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.
Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Dupilumab, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.
If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.
